SCHEMBL6166689

SCHEMBL6166689

Cc1ccc(S(=O)(=O)NC(C)(C)C)c(-c2ccc(-c3ccnc(-c4cccc(C#N)c4)c3C(N)=O)cc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1E P49674 2/20 0.41
CSNK1D P48730 1/20 0.41
GRM5 P41594 1/20 0.37
ALOX5AP P20292 6/20 0.37
FEN1 P39748 6/20 0.37
LRRK2 Q5S007 1/20 0.36
SGK1 O00141 1/20 0.35
KIT P10721 1/20 0.35
PDGFRA P16234 1/20 0.35
CTPS1 P17812 1/20 0.35
GRM2 Q14416 1/20 0.35
ELANE P08246 1/20 0.35
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
F10 P00742 1/20 0.34
RIPK2 O43353 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6166679 0.94 CSNK1E (0.41) CSNK1ECSNK1DGRM5ALOX5APFEN1
SCHEMBL6165046 0.91 ALOX5AP (0.42) CSNK1ECSNK1DALOX5APFEN1SGK1
SCHEMBL6164560 0.91 ALOX5AP (0.45) CSNK1ECSNK1DALOX5APFEN1F10
SCHEMBL6164546 0.87 CSNK1E (0.43) CSNK1ECSNK1DALOX5APFEN1
SCHEMBL6166685 0.85 CSNK1E (0.40) CSNK1ECSNK1DALOX5APFEN1LRRK2
SCHEMBL6166683 0.81 F10 (0.46) GRM5LRRK2CTPS1ELANEPSEN1
SCHEMBL6164550 0.78 ALOX5AP (0.46) CSNK1ECSNK1DALOX5APFEN1SGK1
SCHEMBL6165044 0.72 F10 (0.46) ALOX5APFEN1LRRK2CTPS1F10
SCHEMBL6162237 0.72 MAPK14 (0.34) ALOX5APFEN1GRM2F10
SCHEMBL6164549 0.71 F10 (0.56) ALOX5APFEN1LRRK2F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1254136-A4 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG CHEM INVESTMENT LTD (KR) 2005-06-01 EP disclosed
US-20030065176-A1 Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof LG CHEM INVESTMENT LTD. (KR) 2003-04-03 US disclosed
EP-1254136-A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG Chem Investment, Ltd. (KR) 2002-11-06 EP disclosed
WO-2001055146-A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG CHEM INVESTMENT LTD. (KR) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065176-A1 Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof F2, F12, TFPI CSNK1E 1373/4885CSNK1D 1067/4885GRM5 4242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.